Company profile: Stat-Dx
1.1 - Company Overview
Company description
- Provider of near-patient testing products for healthcare professionals, primarily for short turnaround time applications and critical care.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Stat-Dx
DNAe
HQ: United Kingdom
Website
- Description: Provider of rapid near-patient molecular diagnostics, offering the LiDia-SEQ platform for direct-from-specimen DNA sequencing on a microchip; BSI/AMR test detecting bloodstream infections and antimicrobial resistance from whole blood; a sample preparation system extracting pathogens via immunomagnetic beads; semiconductor sequencing technology; and an oncology program for tumor DNA monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNAe company profile →
Sherlock Biosciences
HQ: United States
Website
- Description: Provider of engineering biology-based molecular diagnostics leveraging CRISPR and synthetic biology, including SHERLOCK for DNA/RNA detection and INSPECTR for instrument-free ambient tests, plus an FDA-authorized CRISPR SARS-CoV-2 kit. Offers global health partnerships to develop and distribute affordable infectious disease diagnostics and an internship & co-op program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sherlock Biosciences company profile →
Vicebio
HQ: United Kingdom
Website
- Description: Provider of next-generation respiratory virus vaccines leveraging Molecular Clamp platform technology to stabilize viral glycoproteins in pre-fusion conformation, delivering broad protection and ready-to-use formulations. Pipeline includes bivalent RSV/hMPV (VXB-241), trivalent RSV-hMPV-PIV3, influenza A, SARS-CoV-2, and candidates for MERS, Ebola, and Nipah.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicebio company profile →
SaNOtize
HQ: Canada
Website
- Description: Provider of platform-based nitric oxide topical therapies for upper respiratory and dermal infections, including a Nitric Oxide Nasal Spray (NONS) that reduces respiratory viral RNA load within 24–72 hours, a physician-provided Foot Cleanser for plantar warts, and a Gel Cleanser for nails and skin in development, with additional cleansers and wellness products planned for US launch in 2025–2026.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SaNOtize company profile →
NovaBay Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical eye care products, including Avenova Antimicrobial Lid and Lash Solution, Novawipes by Avenova, Avenova Lubricant Eye Drops, and Avenova Moist Heating Eye Compress, plus proprietary hypochlorous acid wound care solutions: NeutroPhase for cleansing and irrigating wounds (China) and PhaseOne for cleansing post-surgical wounds (US, professional use).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaBay Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Stat-Dx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Stat-Dx
2.2 - Growth funds investing in similar companies to Stat-Dx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Stat-Dx
4.2 - Public trading comparable groups for Stat-Dx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →